@article{be524a5df1fc4d87b058307d95384a1e,
title = "Habitual exercise levels are associated with cerebral amyloid load in presymptomatic autosomal dominant Alzheimer's disease",
abstract = "Introduction The objective of this study was to evaluate the relationship between self-reported exercise levels and Alzheimer's disease (AD) biomarkers, in a cohort of autosomal dominant AD mutation carriers. Methods In 139 presymptomatic mutation carriers from the Dominantly Inherited Alzheimer Network, the relationship between self-reported exercise levels and brain amyloid load, cerebrospinal fluid (CSF) Aβ42 and CSF tau levels was evaluated using linear regression. Results No differences in brain amyloid load, CSF Aβ42, or CSF tau were observed between low and high exercise groups. Nevertheless, when examining only those already accumulating AD pathology (i.e., amyloid positive), low exercisers had higher mean levels of brain amyloid than high exercisers. Furthermore, the interaction between exercise and estimated years from expected symptom onset was a significant predictor of brain amyloid levels. Discussion Our findings indicate a relationship exists between self-reported exercise levels and brain amyloid in autosomal dominant AD mutation carriers.",
keywords = "Alzheimer's disease, Amyloid β, Dementia, Genetics, Physical activity, Tau",
author = "{The Dominantly Inherited Alzheimer Network} and Brown, {Belinda M.} and Sohrabi, {Hamid R.} and Kevin Taddei and Gardener, {Samantha L.} and Rainey-Smith, {Stephanie R.} and Peiffer, {Jeremiah J.} and Chengjie Xiong and Fagan, {Anne M.} and Tammie Benzinger and Virginia Buckles and Erickson, {Kirk I.} and Roger Clarnette and Tejal Shah and Masters, {Colin L.} and Michael Weiner and Nigel Cairns and Martin Rossor and Graff-Radford, {Neill R.} and Stephen Salloway and Jonathan V{\"o}glein and Christoph Laske and James Noble and Schofield, {Peter R.} and Bateman, {Randall J.} and Morris, {John C.} and Martins, {Ralph N.}",
note = "Funding Information: Data collection and sharing for this project was supported by the Dominantly Inherited Alzheimer Network (DIAN; UF1 AG032438 ; to R.J.B. and J.C.M.) funded by the National Institute on Aging , the German Center for Neurodegenerative Diseases (DZNE), the Medical Research Council Dementias Platform UK (M.R.) ( MR/L023784/1 and MR/009076/1 ), and National Institute for Health Research Queen Square Dementia Biomedical Research Unit . B.M.B. received research support from the Alzheimer's Australia Dementia Research Foundation (G1001605), NHMRC National Institute of Dementia (APP1097105), and the Brain Foundation . J.C.M. and R.J.B. received research support from the National Institute of Health . This manuscript has been reviewed by DIAN study investigators for scientific content and consistency of data interpretation with previous DIAN study publications. The DIAN Expanded Registry welcomes contact from any families or treating clinicians interested in research about autosomal dominant familial Alzheimer's disease. Funding Information: R.J.B. reports grants from Eli Lilly, Roche, Pharma Consortium (AbbVie, AstraZeneca, Biogen, Eisai, Eli Lilly and Company, Hoffmann La-Roche Inc, Janssen, Pfizer, Sanofi-Aventis), and Tau SILK/PET Consortium (Biogen/AbbVie/Lilly); nonfinancial support from Avid Radiopharmaceuticals; personal fees and other from Washington University; personal fees and nonfinancial support from Roche, IMI, FORUM, and Pfizer; and personal fees from Merck, Johnson and Johnson, outside the submitted work. J.C.M. is currently participating in clinical trials of antidementia drugs from Eli Lilly and Company, Biogen, and Janssen. J.C.M. serves as a consultant for Lilly USA and receives research support from Eli Lilly/Avid Radiopharmaceuticals. T.B. receives grant funding from Avid Radiopharmaceuticals/Eli Lilly and participates in clinical trials sponsored by Eli Lilly, Avid Radiopharmaceuticals, Roche, and Pfizer. All other authors have declared no conflicts of interest. Publisher Copyright: {\textcopyright} 2017 the Alzheimer's Association",
year = "2017",
month = nov,
doi = "10.1016/j.jalz.2017.03.008",
language = "English (US)",
volume = "13",
pages = "1197--1206",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
publisher = "Elsevier Inc.",
number = "11",
}